313 related articles for article (PubMed ID: 34104091)
1. Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout.
Yen FS; Wei JC; Chang CL; Yang CC; Hsu CC; Hwu CM
Int J Med Sci; 2021; 18(12):2599-2606. PubMed ID: 34104091
[No Abstract] [Full Text] [Related]
2. Urate-lowering therapy exerts protective effects against hypertension development in patients with gout.
Lin KH; Yen FS; Li HL; Wei JC; Hsu CC; Yang CC; Hwu CM
J Hum Hypertens; 2021 Apr; 35(4):351-359. PubMed ID: 32366929
[TBL] [Abstract][Full Text] [Related]
3. Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout.
Yen FS; Hsu CC; Li HL; Wei JC; Hwu CM
PLoS One; 2020; 15(6):e0234909. PubMed ID: 32574194
[TBL] [Abstract][Full Text] [Related]
4. Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study.
Roughley M; Sultan AA; Clarson L; Muller S; Whittle R; Belcher J; Mallen CD; Roddy E
Arthritis Res Ther; 2018 Oct; 20(1):243. PubMed ID: 30376864
[TBL] [Abstract][Full Text] [Related]
5. Association between Gout, Urate-Lowering Therapy, and Risk of Developing Type 2 Diabetes Mellitus: A Nationwide Population-Based Retrospective Cohort Study.
Fang YJ; Chung YL; Lin CL; Lim YP
Biomed Res Int; 2020; 2020():6358954. PubMed ID: 32775432
[TBL] [Abstract][Full Text] [Related]
6. Urate-Lowering Therapy May Prevent the Development of Coronary Artery Disease in Patients With Gout.
Yen FS; Hsu CC; Li HL; Wei JC; Hwu CM
Front Med (Lausanne); 2020; 7():63. PubMed ID: 32175324
[TBL] [Abstract][Full Text] [Related]
7. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
Chung TT; Yu KH; Kuo CF; Luo SF; Chiou MJ; Lan WC; Chen JS; Tseng WY; Hsieh AH; Wang LC
Arthritis Res Ther; 2019 Sep; 21(1):210. PubMed ID: 31533805
[TBL] [Abstract][Full Text] [Related]
8. Burden and management of gout in a multi-ethnic Asian cohort.
Chua CKT; Cheung PP; Santosa A; Lim AYN; Teng GG
Rheumatol Int; 2020 Jul; 40(7):1029-1035. PubMed ID: 31758246
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Safety of Urate Lowering Therapies.
Kang EH; Kim SC
Curr Rheumatol Rep; 2019 Jul; 21(9):48. PubMed ID: 31342190
[TBL] [Abstract][Full Text] [Related]
10. Gout, urate-lowering therapy, and uric acid levels among adults in the United States.
Juraschek SP; Kovell LC; Miller ER; Gelber AC
Arthritis Care Res (Hoboken); 2015 Apr; 67(4):588-92. PubMed ID: 25201123
[TBL] [Abstract][Full Text] [Related]
11. Treat-to-target urate-lowering therapy and hospitalizations for gout: results from a nationwide cohort study in England.
Russell MD; Roddy E; Rutherford AI; Ellis B; Norton S; Douiri A; Gulliford MC; Cope AP; Galloway JB
Rheumatology (Oxford); 2023 Jul; 62(7):2426-2434. PubMed ID: 36355461
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and treatment of gout among patients with chronic kidney disease in the Irish health system: A national study.
Mohammed E; Browne LD; Kumar A U A; Adeeb F; Fraser AD; Stack AG
PLoS One; 2019; 14(1):e0210487. PubMed ID: 30682034
[TBL] [Abstract][Full Text] [Related]
13. Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review.
Terkeltaub R
Drugs; 2023 Nov; 83(16):1501-1521. PubMed ID: 37819612
[TBL] [Abstract][Full Text] [Related]
14. Effects of uric acid-lowering therapy (ULT) on renal outcomes in CKD patients with asymptomatic hyperuricemia: a systematic review and meta-analysis.
Luo Y; Song Q; Li J; Fu S; Yu W; Shao X; Li J; Huang Y; Chen J; Tang Y
BMC Nephrol; 2024 Feb; 25(1):63. PubMed ID: 38395818
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with initiation and persistence of urate-lowering therapy.
Dehlin M; Ekström EH; Petzold M; Strömberg U; Telg G; Jacobsson LT
Arthritis Res Ther; 2017 Jan; 19(1):6. PubMed ID: 28095891
[TBL] [Abstract][Full Text] [Related]
16. Adherence with urate-lowering therapies among male patients with gout in a routine clinical setting.
Lee S; So MW
Mod Rheumatol; 2016 Nov; 26(6):950-955. PubMed ID: 27142782
[TBL] [Abstract][Full Text] [Related]
17. Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia.
Levy GD; Rashid N; Niu F; Cheetham TC
J Rheumatol; 2014 May; 41(5):955-62. PubMed ID: 24692523
[TBL] [Abstract][Full Text] [Related]
18. Lowering Serum Urate With Urate-Lowering Therapy to Target and Incident Fracture Among People With Gout.
Wei J; Choi HK; Dalbeth N; Lane NE; Wu J; Lyu H; Zeng C; Lei G; Zhang Y
Arthritis Rheumatol; 2023 Aug; 75(8):1456-1465. PubMed ID: 36940260
[TBL] [Abstract][Full Text] [Related]
19. Serum Urate Monitoring Among Older Adults With Gout: Initiating Urate-Lowering Therapy in Ontario, Canada.
Kwok TSH; Kuriya B; Hawker G; Li P; Choy G; Widdifield J
Arthritis Care Res (Hoboken); 2023 Dec; 75(12):2463-2471. PubMed ID: 37248652
[TBL] [Abstract][Full Text] [Related]
20. Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial.
Mu Z; Wang W; Wang J; Lv W; Chen Y; Wang F; Yu X; Wang Y; Cheng B; Wang Z
Clin Rheumatol; 2019 Dec; 38(12):3511-3519. PubMed ID: 31410659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
